MicroRNAs (miRNAs) are a class of small endogenous single-stranded noncoding RNA molecules that have important roles in several biological processes. Research in human and laboratory animals has shown that miRNAs can regulate genes associated with type 2 diabetes mellitus and metabolic syndrome, and that the levels of specific miRNAs circulating in the bloodstream can serve as potential biomarkers for the diagnosis and prognosis of these diseases. We hypothesized that insulin-resistant (IR) horses would have a different circulating miRNA profile than those that are healthy. Fifteen nonpregnant mares housed at the Virginia Tech Middelburg Agricultural Research and Extension Center were evaluated for insulin sensitivity, with the frequent sampling intravenous glucose tolerance test. Selected mares, representing the most insulin-sensitive (IS, n ¼ 3) and IR (n ¼ 3) states, and paired for age, weight, and body condition, underwent miRNA profiling. Serum samples were collected, miRNA extracted, and microarray analysis performed to investigate the presence and relative amount of 340 equine miRNAs. Confirmation by quantitative real-time polymerase chain reaction revealed that miRNA was present in the serum of all animals. Results demonstrated different miRNA profiles between groups: Six miRNAs were expressed only in IS mares, five miRNAs were found to have lower quantity in IR mares relative to the IS ones, and three miRNAs were higher quantity in IR mares relative to the IS ones. The novel results of this preliminary study suggest potential new tools that could be developed for the diagnosis and treatment of metabolic syndrome in horses.
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Introduction
Insulin resistance (IR) is a prevalent pathophysiological disorder among domestic horses, and a key player in a large constellation of comorbid conditions, which includes obesity and regional adiposity, chronic low-grade systemic inflammation, equine metabolic syndrome, pituitary pars intermedia dysfunction, and endocrinopathic laminitis [1] . Exact mechanisms for how, why, and when IR occurs in horses are not completely elucidated, and remain active areas of research [2, 3] . Myriad factors, similar to those in human sufferers of IR, may play a part, including reduced density of cell-surface insulin receptors, malfunction of these receptors, defects in the internal cell signaling pathways, and breakdown of the internal glucose-shuttling machinery within the cell [4] .
Complicating matters is the dependence of IR on both environmental and intrinsic factors. Contemporary management practices, including unrestricted access to pasture, relatively sedentary lifestyles, and high-glycemic concentrated diets, have been associated with increased insulin resistance and compensatory increase in insulin secretion. Genotypes that favored fat and glycogen storage were beneficial for populations facing cycles of feast and famine, but present-day exposure to an overfed state has led to increased incidence of obesity and IR [5] . Because regulation of glucose homeostasis is a core requirement for any animal, insulin dysregulation may manifest across the body, affecting systems that regulate immunology, circulation, reproduction, and growth [6, 7] .
Insulin measurement, demonstrating hyperinsulinemia either fasting, fed or sugar challenged, is sufficient to diagnose insulin resistance. However, diagnosis of IR is performed most accurately by performing dynamic tests such as the euglycemic hyperinsulinemic clamp or the frequently sampled intravenous glucose tolerance (FSIGT) test with minimal model analysis [7] . However, these tests are time-consuming, expensive, and impractical for field situations. Single-sample and proxy assessments of glucose and insulin have been developed [8] , but these tests lack specificity, rendering them of limited diagnostic or prognostic applicability to individual animals.
Since their discovery in 1993, microRNAs (miRNAs) have emerged as exciting key regulators of biological processes and promising biomarkers for disease. These small (w22 nucleotides in length) noncoding RNA molecules bind to specific mRNA targets and promote their degradation or translational inhibition, effectively "turning off" genes in a post-transcriptional manner. One miRNA may regulate hundreds of mRNAs, and thus single miRNAs may have a substantial influence on gene expression networks. For this reason, differential miRNA expression patterns between healthy and diseased animals are especially rich in biological and physiological information, as variation in expression of hundreds of mRNAs may be revealed in the expression patterns of one or a few regulatory miRNA [9] .
Profiling of miRNA has quickly become a powerful and attractive tool in disease research that offers two distinct benefits [10] . First, measuring miRNA expression facilitates better understanding of the molecular mechanisms involved in the pathology of interest, as it can allow system-level studies of gene regulation, especially when paired with mRNA data. Secondly, miRNAs have been shown to be incredibly robust in circulation and are measurable to a much higher sensitivity than cell-free circulating proteins. For this reason, miRNA profiling is of great interest to scientists wishing to develop biomarkers for diverse biomedical applications, including cancer, autoimmune, cardiovascular, and metabolic diseases [9, 11] .
In human metabolic research, miRNAs have already been identified, which can separate groups of patients into clinically relevant classes, such as prediabetic or type 2 diabetic versus healthy cohorts [12, 13] . A large suite of miRNAs has been directly implicated in aberrant beta-cell development and functioning, adipogenesis, skeletal muscle insulin signaling pathways, and glucose and lipid metabolism [12, 14, 15] . In some cases, these miRNAs are detectable several years before signs of type 2 diabetes mellitus (T2D) or metabolic syndrome manifest clinically [11, 16] .
In this study, it was hypothesized that IR horses would exhibit differential circulating miRNA profiles when compared with healthy animals. The characterization of circulating miRNA profiles associated with equine IR, followed by the identification of potential gene target components of pathways triggered by, or contributing to, the pathology of insulin resistance could help on the development of simple, noninvasive novel biomarkers that would assist clinicians in the diagnosis and treatment of equine insulin resistance. Therefore, this study aimed to measure insulin sensitivity in a group of animals and to compare miRNAs between insulin-resistant (IR) and insulinsensitive horses. Identification of candidate genes important for equine insulin resistance and its associated conditions was also pursued.
Materials and Methods

Animals and Sampling
Initially, 15 nonpregnant light horse type Warmblood cross mares maintained on ad libitum pasture at the Virginia Tech Middleburg Agricultural Research and Extension Center (Middleburg, VA) were metabolically characterized using the FSIGT [17] , a "gold standard" dynamic method for measuring equine insulin sensitivity. Briefly, on the evening before the test, horses were housed overnight in stalls allowed ad libitum access to water and hay with known composition and low sugar content to maintain an unperturbed state before sampling. On the morning of the test, baseline blood samples were taken at À30 and 0 minutes, and a dose of 50% dextrose (300 mg/kg body weight [BWT]; Vedco, Inc, St Joseph, MO) was administered intravenously over 30 seconds via indwelling jugular catheters. At 20-minute postdextrose, insulin (10 mIU/kg BWT; Humulin R, Lilly, Lake Forest, IL) was administered intravenously, and blood sampling continued at 2-30 minute intervals until 180 minutes postdextrose infusion. Horses were provided ad libitum access to water throughout the FSIGT, and all necessary precautions were taken to ensure the test was performed in a quiet environment to minimize untoward effects on insulin concentrations. The FSIGT was performed in May 2014, when the animals are usually more likely to develop metabolic syndrome symptoms because of rich pasture conditions. Pasture nutrient content at the time of the FSIGT is shown in Table 1 .
Sample Handling and Insulin Sensitivity Analysis
Plasma tubes were spun at 2,000g for 10 minutes at 4 C to separate plasma. Serum tubes were allowed to clot for 1 hour at room temperature before centrifuging at 1,500g for 10 minutes at 4 C to separate serum. Plasma and serum samples were aliquoted into 2.5 mL cryovial tubes and stored at À80 C for later use in downstream analyses. All FSIGT tests were performed in the span of 1 week to reduce variation because of the time of collection.
Plasma was analyzed for glucose by enzymatic assay using the YSI 2700 SELECT Biochemistry Analyzer (Yellow Springs, OH) with YSI 2365 glucose membranes, YSI 2747 glucose/L-Lactate standard, and YSI 2357 buffer concentrate kit. Insulin was analyzed using Siemens Coat-A-Count Insulin Radioimmunoassay kit (Siemens, Los Angeles, CA), previously validated for horses [18] . Insulin levels above the kit standards were diluted with charcoal-stripped equine plasma [19] .
Insulin sensitivity index, acute insulin response to glucose (within 20 minutes after glucose administration), glucose effectiveness, and disposition index were determined by the minimal model of glucose and insulin dynamics using specialized software (MINMOD Millennium, version 6.02) [8] . Serum collected during the À30-minute baseline measurement of the FSIGT was used for further analyses.
Isolation of RNA and cDNA Synthesis
Total RNA was isolated from equine serum samples according to manufacturer's protocols using TRI Reagent BD-RNA/DNA/Protein Isolation Reagent for Blood Derivatives (Molecular Research Center, Cincinnati, OH). Samples were lysed and separated by chloroform into RNA and protein layers. RNA was precipitated with isopropanol and washed with 75% ethanol. All samples were then treated with DNAfree DNase Treatment and Removal Reagent (Invitrogen/Life Sciences, Grand Island, NY) to remove any DNA contamination. RNA purity values were assessed using the NanoDrop ND-1000 Spectrophotometer (Thermo Scientific, Wilmington, DE). Typically, 260/280 values of above 1.8 are considered acceptable for RNA quantification by polymerase chain reaction (PCR). For this RNA isolation, using chloroform causes the nanodrop reading to have lower 260/280 values and therefore values of 1.7 were accepted for PCR. Samples were then stored at À80 C until further quantitative realtime PCR (qRT-PCR) analysis. cDNA was generated using miScript (Qiagen Valencia, CA) per the manufacturer's protocol. Four mL 5Â miScript RT Buffer, 1 mL reverse transcriptase mix, and 1 mg of RNA and water were used in a 20 mL solution and incubated for 60 minutes at 37 C, and then 5 minutes at 95 C. cDNA reaction was then immediately added to qRT-PCR master mix for PCR analysis [20] .
Selection of miRNA and Primer Design
Equine miRNA forward primer sequences were obtained by an in-silico detection model [21] and validated in the horse via small RNA-seq. Of all the 340 equine miRNAs, 250 were conserved human miRNAs and 75 were equine-specific miRNAs with human homologues, but different nucleotide sequences. The remaining 15 miRNAs were equine-specific, but had no apparent human homologue [20] .
MicroRNAs were considered present if the cross-point cycle (Cp) value was <40.0 and the melt curves appeared normal. Samples were run in duplicate and normalized to internal controls, that is, miRNAs present in all samples with a standard deviation (SD) between samples of less than one.
Real-time Quantitative PCR
Quantitative real-time polymerase chain reaction was performed using the LightCycler 480 PCR system (Roche). The following three controls were used: One master mix RTrxn control as a negative control and two master mix RTrxn controls with one random primer each. Quantitative real-time polymerase chain reaction was performed on 384 well plates. Each well contained 6 mL of total reaction, including 2Â QuantiTect SYBR Green PCR Master Mix, 10Â miScript Universal reverse primer (Qiagen), and miRNA specific forward primer and 0.1 mL of cDNA. Analysis was performed using the LightCycler 480 PCR system. Cycle conditions began with reaction initiation at 95 C for 15 minutes, followed by 45 cycles of 94 C for 15 seconds to denature, 55 C for 30 seconds to anneal, and 70 C for 30 seconds for extension. All plates run in duplicate, and miRNAs were considered present at a cycle number of <37 as well as confirmed appropriate by amplification curves and singular melt peaks.
Pathway Analysis
A posterior pathway analysis was performed with DIANA TOOLS miRPath, version 3 [22] , using miRNA differentially and uniquely expressed. Predicted targets were recorded using DIANA-microT-CDS algorithm, and pathways were considered significant with P .05 [23] .
Normalization of miRNA Expression Data and Statistical Analysis
Normalization occurred by taking the geometric mean of all miRNA genes expressed in all six samples that had an SD < 1. Two tailed t tests were performed to compare miRNA profiles between groups. Significant results considered when P < .05 and a trend when P < .1.
Results and Discussion
From the 15 mares used in the study, the three most insulin-sensitive (IS) and the three most IR were chosen for the miRNA profiling. The three most IR horses had elevated values for beta-pancreatic secretion relative to reference range [8] , indicating a high insulin secretion to maintain euglycemia. These horses also had insulin sensitivity values within the lowest quintile reported for horse populations [8] . In contrast, the three most IS horses fell within the normal beta-pancreatic response and highest quintile of the population for insulin sensitivity [8] . Minimal model results used to select the horses with the highest (n ¼ 3) and lowest (n ¼ 3) insulin sensitivity for miRNA profiling are demonstrated in Tables 2 and 3 . Weight and ages were not significantly different (P > .5) between groups. However, body condition scores (BCSs) were lower in IS mares (P < .05).
Results demonstrated different miRNA profiles between groups. The following six miRNAs were expressed only in IS mares (P < .001): esa-mir-208a, esa-mir-299, esa-mir-302a, esa-mir-381, esa-mir-769b, and esa-mir-371-3p. The following five miRNAs were found to have lower quantity in IR mares relative to the IS ones: esa-mir-147b (P ¼ .05), esa-mir-370 (P ¼ .09), esa-mir-376c (P ¼ .02), esa-mir-139-5p (P ¼ .14), and esa-mir-1839 (P < .001). The following three miRNAs were found to have higher quantity in IR mares relative to the IS ones (P < .10): esa-mir-129a-5p (P ¼ .06), esa-mir-770 (P ¼ .02), and esa-mir-140-3p (P ¼ .06). Some of these miRNAs have already been related to metabolic syndrome, obesity, and/or related diseases, in other species as shown by previous studies.
In our study, several of the miRNAs differently expressed between groups were also related to fat metabolism. That could be due to the differences in the BCS between both groups as well.
MiRNAs Found in IS Mares Group Only
Mir-208a has been implicated in cardiac metabolism, obesity, insulin sensitivity, and plasma lipids levels. Inhibition of mir-208a in mice confers resistance to high-fat diet-induced obesity and improves systemic insulin sensitivity and glucose tolerance. MED13 and mir-208a have been identified as central components of the heart in regulation of systemic metabolism [24] . MED13 is negatively regulated by a heart-specific miRNA, mir-208a. MED13 is a regulatory subunit of the mediator complex, and regulates systemic energy homeostasis.
Mir-302a is a negative regulator of adipocyte differentiation; associated with hepatic cholesterol, fatty acid, and glucose metabolism. Mir-302a is involved in adipocyte differentiation via interaction with 3 0 -untranslated region (3 0 -UTR) of peroxisome proliferator-activated receptor gamma (PPARg) mRNA in mice, suggesting that mir-302a may negatively regulate PPARg expression through this direct binding. Expression of mir-302a is decreased during adipocyte differentiation (it might potently inhibit adipogenesis), and it might govern the lipid droplet formation and adipocyte-specific gene expression [25] . Mir302a has also been suggested to have important role in the control of hepatic metabolism on high lipid stimulus. Maternal high-fat diet in mice before conception, pregnancy, and lactation induces reduction of hepatic mir-302a level in offspring. Decrease in mir-302a expression in hepatocytes coincides with a marked ninefold increase in the expression of the mir-302a target gene ELOVL6, which is involved in the formation of long-chain fatty acids. Upregulation of ELOVL6 gene expression may predispose the liver to a hepatic insulin resistance, one of the major characteristics of metabolic syndrome [25] . Mir-302a is also involved in cholesterol transport and efflux. The regulation of mir-302a has shown to be inversely correlated with cellular cholesterol levels. It specifically targets the 3 0 -UTR of mouse and human ABCA1, which has the ability to stimulate the efflux of cholesterol from cells in the periphery playing an important role in the antiatherosclerotic mechanism [26] .
Another miRNA, mir-381, has been shown to be upregulated in obese ovine and their offspring [27] , and also to have a trend for a stronger upregulation during the brown adipocyte differentiation in mouse [26] . Patatin-like phospholipase domain containing 3 (PNPLA3) is a gene consistently involved in the genetic susceptibility of nonalcoholic fatty liver disease in humans. From the same family of mir769b, mir-769-3p has been shown to potentially interact in the 3 0 -UTR of the PNPLA3 [28] . MiR-371b-5p, same family of mir-371-3p, was shown to be upregulated in type 2 diabetic nephropathy patients compared with healthy donors and T2D patients during a urinary exosomal miRNA signature isolation [29] .
MiRNAs Found in Lower Quantity in IR Versus IS Group
Mir-370 is involved in the expression of other genes that affect lipid metabolism. It acts via mir-122 and may have a causative role in the accumulation of hepatic triglycerides by modulating initially the expression of several genes, such as sterol-regulatory element binding protein 1c (SREBP-1c), diacylglycerol acyltransferase-2 (DGAT2), and carnitine palmitoyl transferase 1a (Cpt1a, which controls fatty acid oxidation) [30] . In humans, plasma levels of miR-122 and miR-370 are increased in patients with hyperlipidemia and positively correlated with blood levels of total cholesterol, triglyceride, low-density lipoprotein cholesterol, and associated with coronary artery disease presence [31] . Mir-370 Abbreviations: AIRg, acute insulin response to glucose; BCS, body condition scores; DI, disposition index; Sg, glucose effectiveness; SI, sensitivity index. has been shown to be upregulated in myocardial microvascular endothelial cells from type 2 diabetic Goto-Kakizaki rats compared with those in Wistar rats [32] . Mir-376c is upexpressed in pancreatic islets in rats of T2D. In addition, miRNAs from the same family of mir-376c have been shown to have implication in pancreatic betacells regulation and pancreatic tissue growth (mir-376) [33] , and potential as predictive biomarker in obesity (mir376a) [34] .
Mir-139-5p has been shown to block adipogenesis, in rats, via directly targeting the 3 0 -UTRs of Notch1 and IRS1 mRNAs, a key member of Notch signaling and IRS1/PI3K/ Akt insulin signaling, respectively [35] .
MiRNAs Found in Higher Quantity in IR Versus IS Group
It has been suggested that miR-129-3p, same family as mir-129a-5p, may play a role in glucose and lipid metabolism [36] . MiR-770-5p, same family as mir-770, is increased in human patients with T2D [37] . Mir-140-3p has been considered to be at some extension a specific and relevant miRNA for T2D. Individuals with T2D have been shown to have mir-140-3p upregulated, in comparison with individuals with gestational diabetes mellitus, and downregulated in comparison with individuals with type 1 diabetes mellitus [38] . Expression of mir-140, same family of mir-140-3p, is significantly higher in individuals with normal glucose tolerance versus individuals with T2D, and it is believed to play a role in the link between adipose tissue dysfunction and the development of obesityassociated disorders including T2D [39] . In addition, mir-140-5p has potential to be a biomarker for risk estimation and classification of morbidly obese human patients [40] .
Conclusion
The results of this study were able to support the proposal that IR horses exhibit differential miRNA profiles from healthy animals, in addition to identify possible miRNA profiles with high potential as biomarkers for insulin resistance in equines. The novel results of this preliminary study suggest a potential new tool that could be developed for early diagnosis of equine metabolic syndrome.
